Functional polymorphism of the NQO2 gene is associated with methamphetamine psychosis

Shintaro Ohgake, Kenji Hashimoto, Eiji Shimizu, Hiroki Koizumi, Naoe Okamura, Kaori Koike, Daisuke Matsuzawa, Yoshimoto Sekine, Toshiya Inada, Norio Ozaki, Nakao Iwata, Mutsuo Harano, Tokutaro Komiyama, Mitsuhiko Yamada, Ichiro Sora, Hiroshi Ujike, Yukihiko Shirayama, Masaomi Iyo

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)


Several lines of evidence suggest that genetic factors contribute to the vulnerability of drug abuse such as methamphetamine (MAP), and that dopamine-quinones produced by administration of MAP may be involved in the mechanism of MAP-related symptoms. The detoxification of quinones is catalyzed by a family of proteins designated as quinone oxidoreductases (NQOs). We analysed the polymorphisms of NQO1 and NQO2 genes to elucidate the association with genetic vulnerability to MAP abuse in Japan. The genotype and allele frequencies for the polymorphism (Pro187Ser) of the NQO1 gene did not differ between each subgroup of patients and controls. In contrast, the genotype frequency for the insertion/deletion (I/D) polymorphism in the promoter region of the NQO2 gene was a significant (p = 0.038) difference between patients with prolonged-type MAP psychosis and controls. This study suggests that the NQO2 gene polymorphism contributes to the aetiology of MAP-related psychosis in Japanese.

Original languageEnglish
Pages (from-to)145-148
Number of pages4
JournalAddiction Biology
Issue number2
Publication statusPublished - 06-2005

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Pharmacology
  • Psychiatry and Mental health


Dive into the research topics of 'Functional polymorphism of the NQO2 gene is associated with methamphetamine psychosis'. Together they form a unique fingerprint.

Cite this